ꯃꯔꯨꯑꯣꯏꯕꯥ ꯀꯝꯄꯣꯅꯦꯟꯇꯁꯤꯡ ꯑꯃꯁꯨꯡ ꯑꯦꯛꯁꯅꯒꯤ ꯃꯦꯀꯥꯅꯤꯖꯃꯁꯤꯡ
ꯁꯦꯟꯇ ꯖꯣꯅꯁ ꯋꯔꯠ (ꯍꯥꯏꯄꯦꯔꯤꯀꯝ ꯄꯥꯔꯐꯣꯔꯇꯝ) ꯑꯦꯛꯁꯠꯔꯦꯛꯇꯀꯤ ꯏꯐꯤꯁꯤꯑꯦꯟꯁꯤ ꯑꯁꯤ ꯃꯔꯨꯑꯣꯏꯅꯥ ꯃꯈꯥꯗꯥ ꯄꯤꯔꯤꯕꯥ ꯑꯦꯛꯇꯤꯕ ꯏꯅꯒ꯭ꯔꯦꯗꯤꯌꯦꯟꯇꯁꯤꯡ ꯑꯁꯤꯗꯒꯤ ꯂꯥꯀꯏ:
ꯍꯥꯏꯄꯔꯤꯁꯤꯟ ꯇꯧꯕꯥ ꯌꯥꯏ꯫
ꯐꯣꯇꯣꯁꯦꯟꯁꯤꯇꯤꯕ ꯑꯃꯁꯨꯡ ꯑꯦꯟꯇꯤꯚꯥꯏꯔꯦꯜ ꯄ꯭ꯔꯣꯄꯔꯇꯤꯁꯤꯡ ꯎꯠꯂꯤ, ꯅ꯭ꯌꯨꯔꯣꯠꯔꯥꯟꯁꯃꯤꯇꯔ ꯑꯦꯛꯇꯤꯚꯤꯇꯤ ꯃꯣꯗ꯭ꯌꯨꯜ ꯇꯧꯏ꯫
ꯁ꯭ꯇꯗꯤꯁꯤꯡꯅꯥ ꯇꯥꯛꯂꯤ ꯃꯗꯨꯗꯤ ꯑꯀꯛꯅꯕꯥ ꯀꯟꯁꯦꯟꯠꯔꯦꯁꯅꯁꯤꯡꯗꯥ, ꯃꯁꯤꯅꯥ ꯑꯦꯚꯤꯌꯟ ꯏꯅꯐ꯭ꯂꯨꯑꯦꯟꯖꯥ ꯚꯥꯏꯔꯁ ꯔꯤꯞꯂꯤꯀꯦꯁꯟ ꯑꯁꯤ ꯹꯹.꯹꯹%ꯒꯤ ꯏꯔꯦꯗꯤꯀꯦꯁꯅꯒꯤ ꯆꯥꯡꯒꯥ ꯂꯣꯌꯅꯅꯥ ꯊꯤꯡꯕꯥ ꯉꯃꯒꯅꯤ꯫
ꯍꯥꯏꯄꯔꯐꯣꯔꯤꯟ
ꯃꯔꯨꯑꯣꯏꯕꯥ ꯑꯦꯟꯇꯤꯗꯤꯞꯔꯦꯁꯦꯟꯇ ꯀꯝꯄꯣꯅꯦꯟꯇ, ꯁꯦꯔꯣꯇꯣꯅꯤꯟ ꯑꯃꯁꯨꯡ ꯗꯣꯄꯥꯃꯥꯏꯅꯒꯨꯝꯕꯥ ꯅ꯭ꯌꯨꯔꯣꯠꯔꯥꯟꯁꯃꯤꯇꯔꯁꯤꯡꯒꯤ ꯔꯤꯌꯨꯄꯇꯦꯛ ꯑꯁꯤ ꯊꯤꯡꯗꯨꯅꯥ ꯃꯨꯗ ꯐꯒꯠꯍꯅꯕꯥ꯫
ꯀ꯭ꯂꯤꯅꯤꯀꯦꯜ ꯏꯚꯤꯗꯦꯟꯁꯅꯥ ꯃꯌꯥꯏ ꯑꯣꯏꯕꯥ ꯑꯃꯁꯨꯡ ꯃꯌꯥꯏ ꯑꯣꯏꯕꯥ ꯗꯤꯞꯔꯦꯁꯅꯒꯤꯗꯃꯛꯇꯥ ꯃꯔꯨꯑꯣꯏꯕꯥ ꯏꯐꯦꯛꯇꯁꯤꯡ ꯇꯥꯛꯂꯤ, ꯑꯃꯁꯨꯡ ꯁ꯭ꯇꯗꯤ ꯈꯔꯅꯥ ꯄ꯭ꯔꯦꯁ꯭ꯛꯔꯤꯄꯁꯟ ꯄꯤꯕꯥ ꯍꯤꯗꯥꯀꯁꯤꯡꯒꯥ ꯆꯥꯡꯗꯝꯅꯕꯥ ꯌꯥꯕꯥ ꯏꯐꯤꯁꯤꯑꯦꯟꯁꯤꯒꯤ ꯃꯇꯥꯡꯗꯥ ꯇꯥꯛꯂꯤ꯫
ꯐ꯭ꯂꯦꯕꯣꯅꯣꯏꯗꯁꯤꯡ .
ꯑꯦꯟꯇꯤꯑꯣꯛꯁꯤꯗꯦꯟꯇ ꯑꯃꯁꯨꯡ ꯑꯦꯟꯇꯤ-ꯏꯅꯐ꯭ꯂꯦꯃꯦꯇꯔꯤ ꯁꯄꯣꯔꯠ ꯄꯤꯕꯥ, ꯅ꯭ꯌꯨꯔꯣꯏꯅꯐ꯭ꯂꯦꯃꯦꯁꯟ ꯍꯟꯊꯍꯅꯕꯗꯥ ꯃꯇꯦꯡ ꯄꯥꯡꯏ꯫
ꯁꯥꯏꯟꯇꯤꯐꯤꯛ ꯑꯣꯏꯅꯥ ꯚꯦꯂꯤꯗꯦꯠ ꯇꯧꯔꯕꯥ ꯀꯥꯟꯅꯕꯁꯤꯡ
ꯃꯨꯗ ꯍꯦꯅꯒꯠꯍꯅꯕꯥ ꯑꯃꯁꯨꯡ ꯑꯦꯟꯇꯤꯗꯤꯞꯔꯦꯁꯦꯟꯇ ꯏꯐꯦꯛꯇꯁꯤꯡ
ꯃꯌꯥꯏ ꯑꯣꯏꯕꯥ ꯑꯃꯁꯨꯡ ꯃꯌꯥꯏ ꯑꯣꯏꯕꯥ ꯗꯤꯞꯔꯦꯁꯅꯒꯤ ꯑꯣꯏꯅꯗꯤ: ꯅꯨꯃꯤꯠ ꯈꯨꯗꯤꯡꯒꯤ 300-900mgꯗꯥ ꯁ꯭ꯇꯦꯟꯗꯔꯗꯥꯏꯖ ꯇꯧꯔꯕꯥ ꯑꯦꯛꯁꯠꯔꯦꯛꯇ (0.3% ꯍꯥꯏꯄꯔꯁꯤꯁꯤꯟ)ꯅꯥ ꯅꯨꯃꯤꯠ 4-6ꯅꯤꯒꯤ ꯃꯅꯨꯡꯗꯥ ꯔꯤꯖꯜꯇꯁꯤꯡ ꯎꯠꯂꯤ꯫
ꯌꯨꯖꯔꯒꯤ ꯐꯤꯗꯕꯦꯛ: "ꯊꯥ ꯑꯅꯤꯒꯤ ꯃꯇꯨꯡꯗꯥ ꯁꯤꯖꯤꯟꯅꯔꯕꯥ ꯃꯇꯨꯡꯗꯥ, ꯃꯨꯗ ꯁꯣꯏꯪꯁꯤꯡ ꯑꯁꯤ ꯌꯥꯝꯅꯥ ꯍꯟꯊꯈꯤ꯫"
ꯑꯦꯟꯁꯤꯇꯤ ꯔꯤꯂꯤꯐ ꯑꯃꯁꯨꯡ ꯇꯨꯝꯕꯥ ꯐꯒꯠꯍꯅꯕꯥ
ꯍꯥꯏꯄꯔꯐꯣꯔꯤꯅꯅꯥ GABA ꯔꯤꯁꯦꯞꯇꯔꯁꯤꯡ ꯃꯣꯗ꯭ꯌꯨꯜ ꯇꯧꯏ, ꯃꯁꯤꯅꯥ ꯁ꯭ꯠꯔꯦꯁ-ꯃꯔꯤ ꯂꯩꯅꯕꯥ ꯏꯅꯁꯣꯃꯅꯤꯌꯥ ꯍꯟꯊꯍꯅꯕꯗꯥ ꯃꯇꯦꯡ ꯄꯥꯡꯏ꯫
ꯔꯤꯀꯃꯦꯟꯗ ꯇꯧꯔꯕꯥ: ꯅꯨꯃꯤꯗꯥꯡꯗꯥ ꯌꯥꯝꯅꯥ ꯅꯦꯝꯕꯥ ꯗꯣꯖꯁꯤꯡ; ꯀꯦꯐꯥꯏꯅꯒꯥ ꯂꯣꯌꯅꯅꯥ ꯀꯝꯕꯤꯅꯦꯁꯟ ꯇꯧꯔꯣꯏꯗꯕꯅꯤ꯫
ꯑꯦꯟꯇꯤꯚꯥꯏꯔꯦꯜ ꯑꯦꯞꯂꯤꯀꯦꯁꯅꯁꯤꯡ (ꯇꯣꯄꯤꯀꯦꯜ/ꯚꯦꯇꯦꯔꯤꯅꯥꯔꯤ ꯁꯤꯖꯤꯟꯅꯕꯥ)
ꯍꯥꯏꯄꯥꯔꯁꯤꯁꯤꯅꯅꯥ HSV-1 ꯑꯃꯁꯨꯡ ꯑꯦꯚꯤꯌꯟ ꯏꯅꯐ꯭ꯂꯨꯑꯦꯟꯖꯥ ꯚꯥꯏꯔꯁꯀꯤ ꯃꯥꯌꯣꯛꯇꯥ ꯏꯅꯍꯤꯕꯤꯇꯔ ꯑꯣꯏꯕꯥ ꯏꯐꯦꯛꯇꯁꯤꯡ ꯎꯠꯂꯤ, ꯃꯁꯤꯅꯥ ꯇꯣꯄꯤꯀꯦꯜ ꯐꯣꯔꯃꯨꯂꯦꯁꯅꯁꯤꯡ ꯅꯠꯠꯔꯒꯥ ꯑꯦꯅꯤꯃꯦꯜ ꯐꯤꯗ ꯑꯦꯗꯤꯇꯤꯚꯁꯤꯡꯒꯤꯗꯃꯛꯇꯥ ꯆꯨꯅꯕꯥ ꯑꯣꯏ꯫
ꯇ꯭ꯔꯦꯗꯤꯁꯅꯦꯜ ꯑꯣꯏꯕꯥ ꯑꯁꯣꯛ-ꯑꯄꯟ ꯊꯣꯀꯍꯅꯕꯥ
ꯃꯐꯝ ꯑꯗꯨꯗꯥ ꯀꯨꯄꯁꯤꯜꯂꯕꯥ ꯑꯃꯁꯨꯡ ꯁꯤꯖꯤꯟꯅꯔꯕꯥ, ꯃꯁꯤꯅꯥ ꯍꯦꯃꯣꯁ꯭ꯇꯦꯁꯤꯁ ꯄ꯭ꯔꯃꯣꯠ ꯇꯧꯕꯥ ꯉꯝꯃꯤ ꯑꯃꯁꯨꯡ ꯑꯄꯤꯀꯄꯥ ꯃꯩꯅꯥ ꯆꯥꯀꯄꯥ ꯅꯠꯠꯔꯒꯥ ꯈꯣꯡ ꯍꯥꯝꯂꯕꯥ ꯃꯇꯨꯡꯗꯥ ꯏꯅꯐ꯭ꯂꯦꯃꯦꯁꯟ ꯂꯥꯌꯦꯡꯕꯥ ꯉꯝꯃꯤ꯫
ꯁꯤꯖꯤꯟꯅꯕꯒꯤ ꯄꯥꯎꯇꯥꯀꯁꯤꯡ .
ꯗꯣꯖ ꯑꯣꯏꯕꯥ .: 300-900mg/day (0.3%ꯒꯤ ꯍꯥꯏꯄꯔꯁꯤꯁꯤꯅꯗꯥ ꯁ꯭ꯇꯦꯟꯗꯔꯗꯥꯏꯖ ꯇꯧꯕꯥ), ꯆꯥꯅꯕꯥ ꯆꯤꯟꯖꯥꯛꯀꯥ ꯂꯣꯌꯅꯅꯥ ꯂꯧꯕꯥ ꯗꯣꯖꯁꯤꯡ꯫
ꯂꯥꯌꯦꯡꯕꯒꯤ ꯃꯇꯝ: ꯑꯍꯥꯅꯕꯥ ꯏꯐꯦꯛꯇꯁꯤꯡꯒꯤꯗꯃꯛ ꯌꯥꯃꯗ꯭ꯔꯕꯗꯥ ꯅꯨꯃꯤꯠ 4; ꯊꯥ ꯳-꯶ꯀꯤ ꯑꯣꯏꯅꯥ ꯃꯦꯟꯇꯦꯅꯦꯟꯁ ꯇꯧꯕꯥ꯫
ꯀꯟꯠꯔꯣꯏꯟꯗꯤꯀꯦꯁꯅꯁꯤꯡ .:
SSRIꯁꯤꯡ, ꯑꯣꯔꯦꯜ ꯀꯟꯠꯔꯣꯁꯦꯄꯇꯤꯚꯁꯤꯡ, ꯅꯠꯠꯔꯒꯥ ꯋꯥꯔꯐꯦꯔꯤꯅꯒꯥ ꯂꯣꯌꯅꯅꯥ ꯃꯇꯝ ꯑꯃꯠꯇꯗꯥ ꯁꯤꯖꯤꯟꯅꯔꯣꯏꯗꯕꯅꯤ (ꯑꯦꯐꯤꯀꯦꯁꯟ ꯍꯟꯊꯍꯅꯕꯥ ꯌꯥꯏ ꯅꯠꯠꯔꯒꯥ ꯑꯁꯣꯛ-ꯑꯄꯟ ꯊꯣꯀꯍꯅꯕꯥ ꯌꯥꯏ)꯫
ꯃꯤꯔꯣꯜꯂꯤꯕꯤ/ ꯅꯔꯁꯤꯡ ꯇꯧꯔꯤꯕꯥ ꯅꯨꯄꯤꯁꯤꯡ ꯅꯠꯠꯔꯒꯥ ꯆꯍꯤ 12ꯒꯤ ꯃꯈꯥꯗꯥ ꯂꯩꯕꯥ ꯑꯉꯥꯡꯁꯤꯡꯒꯤꯗꯃꯛ ꯔꯦꯀꯃꯦꯟꯗ ꯇꯧꯗꯦ꯫
ꯌꯨꯖꯔ ꯇꯦꯁ꯭ꯇꯤꯃꯣꯅꯤꯌꯂꯁꯤꯡ
"ꯂꯦꯞꯇꯅꯥ ꯁꯤꯖꯤꯟꯅꯔꯕꯥ ꯃꯇꯨꯡꯗꯥ, ꯋꯥꯔꯛ-ꯃꯔꯤ ꯂꯩꯅꯕꯥ ꯏꯅꯁꯣꯃꯅꯤꯌꯥ ꯑꯁꯤ ꯅꯣꯇꯤꯁ ꯑꯣꯏꯅꯥ ꯐꯒꯠꯂꯀꯈꯤ꯫" -ꯆꯍꯤ ꯳꯵ ꯁꯨꯔꯕꯥ ꯄ꯭ꯔꯣꯐꯦꯁ꯭ꯅꯦꯜ꯫
"ꯑꯦꯛꯁꯔꯁꯥꯏꯖꯒꯥ ꯄꯨꯟꯅꯥ ꯆꯠꯃꯤꯟꯅꯗꯨꯅꯥ, ꯃꯨꯗ ꯁ꯭ꯇꯦꯕꯤꯂꯥꯏꯖ ꯇꯧꯔꯕꯥ-ꯑꯗꯨꯕꯨ ꯅꯨꯃꯤꯠꯀꯤ ꯉꯥꯀꯊꯣꯀꯄꯥ ꯑꯁꯤ ꯇꯉꯥꯏ ꯐꯗꯕꯥ (ꯐꯣꯇꯣꯁꯦꯟꯁꯤꯇꯤꯕ)ꯅꯤ꯫" -ꯆꯍꯤ ꯲꯸ ꯁꯨꯔꯕꯥ ꯐꯤꯠꯅꯦꯁꯀꯤ ꯊꯧꯅꯥ ꯐꯕꯥ꯫
ꯃꯔꯨꯑꯣꯏꯕꯥ ꯆꯦꯀꯁꯤꯟ ꯊꯧꯔꯥꯡꯁꯤꯡ .
ꯐꯣꯇꯣꯁꯦꯟꯁꯤꯇꯤꯕꯤꯇꯤ: ꯁꯤꯖꯤꯟꯅꯕꯗꯥ ꯃꯊꯧ ꯇꯥꯕꯥ ꯅꯨꯃꯤꯠꯀꯤ ꯉꯥꯀꯊꯣꯀꯄꯥ ꯍꯦꯅꯒꯠꯂꯀꯄꯥ; ꯍꯀꯊꯦꯡꯅꯅꯥ ꯌꯨ.ꯚꯤ.
ꯗ꯭ꯔꯒ ꯏꯟꯇꯔꯦꯛꯁꯅꯁꯤꯡ .: 50+ ꯍꯤꯗꯥꯀꯁꯤꯡ-ꯃꯁꯤ ꯁꯤꯖꯤꯟꯅꯗ꯭ꯔꯤꯉꯩ ꯃꯃꯥꯡꯗꯥ ꯍꯦꯜꯊꯀꯦꯌꯔ ꯄ꯭ꯔꯣꯚꯥꯏꯗꯔ ꯑꯃꯥ ꯀꯟꯁꯂꯇꯦꯁꯟ ꯇꯧꯕꯥ ꯌꯥꯕꯥ ꯄꯣꯇꯦꯟꯁꯤꯑꯦꯜ ꯀꯟꯐ꯭ꯂꯤꯛꯇꯁꯤꯡ꯫
ꯀ꯭ꯕꯥꯂꯤꯇꯤ ꯂꯩꯕꯥ: ꯄꯣꯇꯦꯟꯁꯤꯑꯦꯜ ꯁꯣꯌꯗꯅꯥ ꯂꯩꯍꯟꯅꯕꯥ ꯁ꯭ꯇꯦꯟꯗꯔꯗꯥꯏꯖ ꯇꯧꯔꯕꯥ ꯑꯦꯛꯁꯠꯔꯦꯛꯇꯁꯤꯡ (ꯈꯨꯗꯝ ꯑꯣꯏꯅꯥ, 0.3% ꯍꯥꯏꯄꯔꯤꯁꯤꯟ) ꯈꯅꯒꯗꯕꯅꯤ꯫
ꯂꯣꯏꯁꯤꯟꯕ
ꯁꯦꯟꯇ ꯖꯣꯅꯁ ꯋꯔꯠ ꯑꯦꯛꯁꯠꯔꯦꯛꯇ ꯑꯁꯤ ꯃꯨꯗ ꯃꯦꯅꯦꯖꯃꯦꯟꯇꯀꯤꯗꯃꯛꯇꯥ ꯍꯦꯟꯅꯥ ꯄꯥꯝꯅꯕꯥ ꯃꯍꯧꯁꯥꯒꯤ ꯑꯣꯄꯁꯟ ꯑꯃꯅꯤ ꯑꯗꯨꯕꯨ ꯃꯁꯤ ꯂꯥꯌꯦꯡꯕꯅꯤ-ꯄꯨꯝꯅꯃꯛ꯫ ꯀꯥꯟꯅꯕꯥ ꯈ꯭ꯕꯥꯏꯗꯒꯤ ꯌꯥꯝꯅꯥ ꯄꯤꯅꯕꯒꯤꯗꯃꯛ, ꯁꯥꯏꯟꯇꯤꯐꯤꯛ ꯑꯣꯏꯅꯥ ꯁꯤꯖꯤꯟꯅꯕꯥ ꯑꯃꯁꯨꯡ ꯃꯤꯑꯣꯏ ꯑꯃꯒꯤ ꯃꯊꯧ ꯇꯥꯕꯁꯤꯡꯒꯥ ꯆꯨꯅꯕꯥ ꯃꯑꯣꯡꯗꯥ ꯁꯤꯖꯤꯟꯅꯕꯥ꯫
